contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


elicera-therapeutics-includes-the-first-patient-in-the-phase-iii-clinical-study-carma-targeting-b-cell-lymphoma

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Elicera Therapeutics

Gothenburg, November 5, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial...

<div class="abstract">Gothenburg, November 5, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell&nbsp;and gene therapy company developing next generation cancer treatments based on its&nbsp;proprietary commercial technology platform iTANK, announced today that the first patient has been enrolled in the company's Phase I/II clinical study, CARMA. The study aims to evaluate the iTANK-armed CAR T-cell therapy, ELC-301, in patients with hard-to-treat B-cell lymphoma, mantle cell lymphoma, or indolent lymphoma who have not responded to standard treatment or have experienced a relapse of the disease.</div>The study will be conducted in two parts, with the initial phase involving dose escalation in 12 patients to determine the optimal dosing range for treatment with ELC-301. In the next phase, the maximum tolerable dose will be evaluated in an additional 6 patients, with a total of 12 patients expected to receive treatment at this dose level.The study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. According to the company's preliminary timeline, the dose escalation study, including 12 patients in total, is expected to be completed and reported in the second half of 2025. Data from the first dose group of three patients is expected to be reported in first quarter of 2025. Preliminary results from the second part of the study are anticipated approximately 6-12 months later. Following treatment, a follow-up period of at least two years will occur, meaning CARMA is expected to be completed and fully reported in 2028.CARMA is a single-arm, open-label multicenter study aiming to evaluate the safety profile and treatment efficacy of a single dose of ELC-301. It targets patients diagnosed with relapsed or refractory CD20-positive B-cell lymphoma, mantle cell lymphoma, or indolent lymphoma. The study will examine, among other things, the treatment's antitumor effect, toxicity, and tolerability."We are very pleased to finally begin our first clinical evaluation of ELC-301 and reach one of the most important milestones in our company history. It is an important step towards our goal of hopefully offering a new treatment for aggressive forms of B-cell cancer. The clinical development of ELC-301 will also provide us with important insights into our iTANK technology platform, which aims to generate a broad immune response against cancer cells," says Jamal El-Mosleh, CEO of Elicera Therapeutics

Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma